Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Condition: Non-syndromic Retinitis Pigmentosa Intervention: Combination Product: Gene therapy: GS030-DP AND Medical device: GS030-MD Sponsor: GenSight Biologics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials